British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

Todays focus will be on GSK Pharma shares in light of the companys announced topline growth and profitability for the full ...

GlaxoSmithKline Pharmaceuticals Ltd. reported a 36% increase in consolidated net profit to Rs 263 crore for the quarter ended ...

More children stopped using steroid inhalers to control their asthma after GlaxoSmithKline withdrew Flovent from the market.

May 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs. The Indian unit ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Quarterly Net Profit at Rs. 262.87 crore in March 2025 up 35.17% from Rs. 194.48 crore in March 2024. EBITDA stands at Rs. 373.87 crore in March 2025 up 30.23% from Rs. 287.09 crore in March 2024.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as Glindia Limited in November, 1924. The Company s name was changed to Glaxo (India) Limited from Glindia Limited in year 1987 ...